Loading...

Magenta Therapeutics

DB:3MT
Snowflake Description

Flawless balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
3MT
DB
$531M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops novel medicines to extend the curative power of stem cell transplant, gene therapy, genome editing, and cell therapy to patients. The last earnings update was 37 days ago. More info.


Add to Portfolio Compare Print
  • Magenta Therapeutics has significant price volatility in the past 3 months.
3MT Share Price and Events
7 Day Returns
10.1%
DB:3MT
0.4%
DE Biotechs
0.8%
DE Market
1 Year Returns
-
DB:3MT
-5.6%
DE Biotechs
-4.5%
DE Market
3MT Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Magenta Therapeutics (3MT) 10.1% -15.2% 138.9% - - -
DE Biotechs 0.4% 7.3% -6.5% -5.6% 51.9% 10.5%
DE Market 0.8% 6.9% 8.1% -4.5% 10.4% 13.9%
1 Year Return vs Industry and Market
  • No trading data on 3MT.
  • No trading data on 3MT.
Price Volatility
Industry
5yr Volatility vs Market
Related Companies

Value

 Is Magenta Therapeutics undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Magenta Therapeutics. This is due to cash flow or dividend data being unavailable. The share price is €14.524.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Magenta Therapeutics's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Magenta Therapeutics's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:3MT PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-3.13
NasdaqGM:MGTA Share Price ** NasdaqGM (2019-04-25) in USD $16.29
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.58x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 20.1x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Magenta Therapeutics.

DB:3MT PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqGM:MGTA Share Price ÷ EPS (both in USD)

= 16.29 ÷ -3.13

-5.2x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Magenta Therapeutics is loss making, we can't compare its value to the Europe Biotechs industry average.
  • Magenta Therapeutics is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Magenta Therapeutics's expected growth come at a high price?
Raw Data
DB:3MT PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -5.2x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts
-15%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.33x
Germany Market PEG Ratio Median Figure of 268 Publicly-Listed Companies 1.57x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Magenta Therapeutics, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Magenta Therapeutics's assets?
Raw Data
DB:3MT PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $4.37
NasdaqGM:MGTA Share Price * NasdaqGM (2019-04-25) in USD $16.29
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.83x
Germany Market PB Ratio Median Figure of 574 Publicly-Listed Companies 1.87x
DB:3MT PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqGM:MGTA Share Price ÷ Book Value per Share (both in USD)

= 16.29 ÷ 4.37

3.73x

* Primary Listing of Magenta Therapeutics.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Magenta Therapeutics is good value based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess Magenta Therapeutics's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Magenta Therapeutics has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Magenta Therapeutics expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-15%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Magenta Therapeutics expected to grow at an attractive rate?
  • Unable to compare Magenta Therapeutics's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Magenta Therapeutics's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Unable to compare Magenta Therapeutics's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:3MT Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:3MT Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 4 Analysts -15%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.8%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:3MT Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:3MT Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 32 -136 -131 3
2022-12-31 3 -144 -142 3
2021-12-31 0 -114 -124 3
2020-12-31 13 -78 -100 4
2019-12-31 0 -83 -88 4
DB:3MT Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 -42 -58
2018-09-30 -37 -49
2018-06-30 -32 -40
2018-03-31 -28 -42
2017-12-31 -22 -36
2016-12-31 -7 -10

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Magenta Therapeutics is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Unable to determine if Magenta Therapeutics is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:3MT Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (3 months ago) See Below
Future Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below

All data from Magenta Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:3MT Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 -2.02 -1.69 -2.55 3.00
2022-12-31 -2.51 -2.32 -2.61 3.00
2021-12-31 -2.60 -2.42 -2.71 4.00
2020-12-31 -2.40 -1.92 -2.73 5.00
2019-12-31 -2.46 -2.26 -2.54 5.00
DB:3MT Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -3.13
2018-09-30 -4.62
2018-06-30 -14.33
2018-03-31 -19.63
2017-12-31 -19.12
2016-12-31 -65.15

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Magenta Therapeutics will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess Magenta Therapeutics's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Magenta Therapeutics has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Magenta Therapeutics performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Magenta Therapeutics's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Magenta Therapeutics does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
  • Unable to compare Magenta Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Magenta Therapeutics's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Magenta Therapeutics's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Magenta Therapeutics Company Filings, last reported 3 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:3MT Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 -57.60 18.62 41.34
2018-09-30 -48.96 15.70 34.50
2018-06-30 -39.86 12.22 28.29
2018-03-31 -41.50 9.80 32.43
2017-12-31 -35.51 7.83 27.90
2016-12-31 -9.74 3.49 5.78

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Magenta Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Magenta Therapeutics has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Magenta Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Magenta Therapeutics's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Magenta Therapeutics has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Magenta Therapeutics's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Magenta Therapeutics's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Magenta Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Magenta Therapeutics's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Magenta Therapeutics's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Magenta Therapeutics has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Magenta Therapeutics Company Filings, last reported 3 months ago.

DB:3MT Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 145.65 0.00 142.57
2018-09-30 159.78 0.00 159.67
2018-06-30 172.22 0.00 173.43
2018-03-31 40.59 0.00 41.46
2017-12-31 50.32 0.00 51.40
2016-12-31 9.04 0.00 4.51
  • Magenta Therapeutics has no debt.
  • Magenta Therapeutics has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Magenta Therapeutics has sufficient cash runway for 2.9 years based on current free cash flow.
  • Magenta Therapeutics has sufficient cash runway for 2.1 years if free cash flow continues to grow at historical rates of 67.1% each year.
X
Financial health checks
We assess Magenta Therapeutics's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Magenta Therapeutics has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Magenta Therapeutics's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Magenta Therapeutics dividends. Estimated to be 0% next year.
If you bought €2,000 of Magenta Therapeutics shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Magenta Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Magenta Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:3MT Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 4 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 326 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:3MT Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 1.00
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Magenta Therapeutics has not reported any payouts.
  • Unable to verify if Magenta Therapeutics's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Magenta Therapeutics's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Magenta Therapeutics has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Magenta Therapeutics's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess Magenta Therapeutics's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Magenta Therapeutics afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Magenta Therapeutics has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Magenta Therapeutics's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Jason Gardner
COMPENSATION $603,633
AGE 47
TENURE AS CEO 3.2 years
CEO Bio

Mr. Jason Gardner, Ph.D., is Cofounder of Magenta Therapeutics, Inc. and has been its Chief Executive Officer and President since February 2016. Mr. Gardner joined Atlas Venture in November 2015 as an Atlas Advisor to create Magenta and has 21 years combined experience in stem cell science and industry leadership roles. He worked at GSK for 11 years, most recently as Vice President and Head of the R&D Satellite in Boston. He created and led the Regenerative Medicine Unit, established partnerships with The Harvard Stem Cell Institute and The Telethon Institute for Gene Therapy from which the first stem cell medicine (Strimvelis™) was approved. He was formerly a scientist at Progenics Pharmaceuticals and Chiron. Mr. Gardner was the Head of the Center of Excellence for External Drug Discovery (CEEDD) and was as a member of the clinical project team that led the late stage development and NDA approval for Tykerb™ for breast cancer. He has been a Director of Magenta Therapeutics, Inc. since February 2016. He has worked on multiple successful modalities across a range of therapeutic areas from target to launch. Mr. Gardner completed a postdoctoral fellowship in hematopoietic stem cells at Harvard Medical School. He was educated in the UK and holds a D.Phil. from Oxford University and M.A. and B.A. degrees from Cambridge University.

CEO Compensation
  • Insufficient data for Jason to compare compensation growth.
  • Jason's remuneration is about average for companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Magenta Therapeutics management team in years:

1.2
Average Tenure
48
Average Age
  • The average tenure for the Magenta Therapeutics management team is less than 2 years, this suggests a new team.
Management Team

Jason Gardner

TITLE
Co-Founder
COMPENSATION
$604K
AGE
47
TENURE
3.2 yrs

Mike Cooke

TITLE
Chief Scientific Officer
COMPENSATION
$496K
AGE
56
TENURE
2.8 yrs

Alison Lawton

TITLE
Board Advisor
COMPENSATION
$193K
AGE
57
TENURE
1 yrs

Jason Ryan

TITLE
Chief Operating & Financial Officer
AGE
44
TENURE
0.3 yrs

Manisha Pai

TITLE
Vice President of Investor Relations & Communications
TENURE
1.5 yrs

Zoran Zdraveski

TITLE
Chief Legal Officer
AGE
48
TENURE
2 yrs

Meg Woods

TITLE
Head of Culture & People
TENURE
1.1 yrs

Christina Isacson

TITLE
Chief Business Officer
AGE
39

John Davis

TITLE
Chief Medical Officer
AGE
56
TENURE
1.2 yrs

Catherine Monaghan

TITLE
Head of Clinical Development Operations
TENURE
1.1 yrs
Board of Directors Tenure

Average tenure and age of the Magenta Therapeutics board of directors in years:

2.8
Average Tenure
60
Average Age
  • The average tenure for the Magenta Therapeutics board of directors is less than 3 years, this suggests a new board.
Board of Directors

Mike Bonney

TITLE
Chairman
AGE
60
TENURE
2.5 yrs

Jason Gardner

TITLE
Co-Founder
COMPENSATION
$604K
AGE
47
TENURE
3.2 yrs

Alexis Borisy

TITLE
Director
AGE
46
TENURE
3.8 yrs

Tom Daniel

TITLE
Director
COMPENSATION
$35K
AGE
64
TENURE
2.5 yrs

David Scadden

TITLE
Chair of Scientific Advisory Board & Director
COMPENSATION
$100K
AGE
65
TENURE
2.4 yrs

Bruce Booth

TITLE
Director
AGE
44
TENURE
3.2 yrs

Alan Tyndall

TITLE
Member of Scientific Advisory Board
AGE
70

Luigi Naldini

TITLE
Member of Scientific Advisory Board

Robert Negrin

TITLE
Member of Scientific Advisory Board

John DiPersio

TITLE
Member of Scientific Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
22. Mar 19 Sell Atlas Venture L.P. Company 20. Mar 19 20. Mar 19 -14,245 €15.73 €-224,064
27. Jun 18 Buy David Scadden Individual 25. Jun 18 25. Jun 18 6,600 €12.83 €84,645
27. Jun 18 Buy Jason Gardner Individual 25. Jun 18 25. Jun 18 400 €12.83 €5,130
X
Management checks
We assess Magenta Therapeutics's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Magenta Therapeutics has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Magenta Therapeutics, Inc., a clinical-stage biotechnology company, develops novel medicines to extend the curative power of stem cell transplant, gene therapy, genome editing, and cell therapy to patients. It is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a novel stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an antibody-drug conjugate program to prevent acute graft and host diseases. The company was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. Magenta Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Details
Name: Magenta Therapeutics, Inc.
3MT
Exchange: DB
Founded: 2015
$476,829,087
32,444,005
Website: http://www.magentatx.com
Address: Magenta Therapeutics, Inc.
100 Technology Square,
5th Floor,
Cambridge,
Massachusetts, 02139,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqGM MGTA Common Stock Nasdaq Global Market US USD 21. Jun 2018
DB 3MT Common Stock Deutsche Boerse AG DE EUR 21. Jun 2018
Number of employees
Current staff
Staff numbers
59
Magenta Therapeutics employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/25 23:21
End of day share price update: 2019/04/25 00:00
Last estimates confirmation: 2019/03/27
Last earnings filing: 2019/03/19
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.